ReShape awarded Grant to further develop Diabetes Bloc-Stim Neuromodulation device
ReShape Lifesciences has been awarded a US$300,000 Small Business Innovation Research (SBIR) grant for the development of ReShape’s...
top of page
Browse by category
Search
Use of avexitide in patients with post-bariatric hypoglycaemia and hyperinsulinemic hypoglycaemia
Phase 2b results of avexitide (Eiger BioPharmaceuticals) in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic...
Zealand Pharma gain FDA approval for Zegalogue (dasiglucagon) injection for hypoglycaemia
Zealand Pharma has received approval from the FDA for Zegalogue (dasiglucagon) injection, for the treatment of severe hypoglycaemia in...
PREVENT Study: Positive results of Avexitide in post-bariatric hypoglycaemia patients
Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe...
Dasiglucagon effective in preventing post-gastric bypass hypoglycaemia
Post-op hypoglycaemia - Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycaemia after meals in individuals who...
Browse by tag
bottom of page